Clinical Trial Update: Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial [Phase 1]

View source ↗

Summary

Phase I trial assessing safety and early efficacy of XS228, iPSC-derived motor neuron progenitor cells, in subacute spinal cord injury. The study is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• XS228

Snippet

Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Conditions: Spinal Cord Injury, Safety | Phase 1 | Status: RECRUITING